Pure Global

Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients - Trial NCT06373744

Access comprehensive clinical trial information for NCT06373744 through Pure Global AI's free database. This phase not specified trial is sponsored by Sun Yat-sen University and is currently Completed. The study focuses on Breast Cancer. Target enrollment is 597 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06373744
Completed
drug
Trial Details
ClinicalTrials.gov • NCT06373744
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients

Study Focus

Breast Cancer

cyclophosphamide , methotrexate , vinorelbine ,capecitabine

Observational

drug

Sponsor & Location

Sun Yat-sen University

Guangzhou, China

Timeline & Enrollment

N/A

Jan 01, 2023

Jan 01, 2024

597 participants

Primary Outcome

Progression free survival

Summary

The goal of this observational study is to learn about the effects of metronomic chemotherapy
 in advanced breast cancer patients. The main question it aims to answer is:
 
 How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups
 of metronomic chemotherapy.

ICD-10 Classifications

Malignant neoplasm of breast
Malignant neoplasm of breast
Carcinoma in situ of breast, unspecified
Malignant neoplasm: Breast, unspecified
Other carcinoma in situ of breast

Data Source

ClinicalTrials.gov

NCT06373744

Non-Device Trial